Septerna (NASDAQ:SEPN – Get Free Report) and Maze Therapeutics (NASDAQ:MAZE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Septerna and Maze Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Septerna | $45.95 million | 39.95 | -$48.88 million | ($1.29) | -29.93 |
| Maze Therapeutics | $167.50 million | 10.23 | -$131.12 million | ($2.65) | -11.83 |
Septerna has higher earnings, but lower revenue than Maze Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Septerna has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Comparatively, Maze Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.
Profitability
This table compares Septerna and Maze Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Septerna | -61.29% | -14.98% | -10.03% |
| Maze Therapeutics | N/A | -38.39% | -32.57% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Septerna and Maze Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Septerna | 1 | 1 | 8 | 1 | 2.82 |
| Maze Therapeutics | 1 | 0 | 9 | 3 | 3.08 |
Septerna presently has a consensus target price of $56.78, suggesting a potential upside of 47.05%. Maze Therapeutics has a consensus target price of $65.50, suggesting a potential upside of 109.00%. Given Maze Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Septerna.
Summary
Maze Therapeutics beats Septerna on 7 of the 13 factors compared between the two stocks.
About Septerna
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
